Press Releases

Nymox Reports on Symposium, Panel Discussion and Podium Presentation on Fexapotide at American Urological Association New York Section Annual Meeting in Havana

November 7, 2017:

Nymox Pharmaceutical Corporation is pleased to report on the two data presentations which were held on Fexapotide Triflutate studies at the Annual Meeting of the American Urological Association, New York Section in Havana, November 6.


Nymox Announces Two Data Presentations for Company’s BPH Drug at New York American Urological Association Meeting November 6

October 26, 2017:

Nymox Pharmaceutical Corporation is pleased to announce that two data presentations of the Company’s new drug Fexapotide Triflutate will be held at the November meeting of the American Urological Association, New York Section.


Nymox Reports on Symposium, Panel Discussion with Abstract on Fexapotide at American Urological Association Northeast Sectional Annual Meeting in Savannah

October 13, 2017:

Nymox Pharmaceutical Corporation is pleased to report on the Symposium which was held on Fexapotide Triflutate studies at the Annual Meeting of the American Urological Association, Northeast Section in Savannah, October 12 at 4 pm.


Nymox Reports on Symposium and Panel Discussion on Fexapotide at American Urological Association Northeast Sectional Annual Meeting in Savannah October 12

October 10, 2017:

Nymox Pharmaceutical Corporation is pleased to report on the Symposium on Fexapotide Triflutate studies to be held at the Annual Meeting of the American Urological Association Northeastern Section, in Savannah GA this week.


Nymox Announces October 12 Symposium for Company’s BPH Drug at American Urological Association Meeting

September 25, 2017:

Nymox Pharmaceutical Corporation is pleased to announce that an important large symposium and panel assessment of the Company’s new drug Fexapotide Triflutate will be held at the October meeting of the American Urological Association, Northeast Section.


Nymox Announces Validation by the European Member States of European Marketing Authorization Application for Fexapotide Triflutate for Benign Prostatic Hyperplasia

September 14, 2017:

Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to announce today that the European Member States for Nymox’s Marketing Authorization Application (MAA) for Fexapotide Triflutate for the treatment of benign prostatic hyperplasia (BPH, prostate enlargement) have accepted the Company’s MAA.


AUA Meeting in Florida September 16 Postponed Due to Hurricane

September 11, 2017:

Nymox Pharmaceutical Corporation (NASDAQ:NYMX) The September 16 AUA Meeting in Amelia Island, Florida has been postponed due to the hurricane disaster in Florida.


Nymox Announces Private Placements of $3 Million

August 9, 2017:

Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to announce recent completion of private placements with proceeds totaling US $3.0 million.


Nymox Announces Symposium for Company’s BPH Drug at American Urological Association Meeting in September

August 7, 2017:

Nymox  Pharmaceutical Corporation  is pleased to announce that an important large symposium and panel assessment of the Company’s new drug Fexapotide Triflutate will be held at the September meeting of the American Urological Association, MidAtlantic Section.


Sexual Function Improves in First-Line Patients Given Fexapotide Treatment in Nymox U.S. BPH Long-Term Clinical Trials

May 31, 2017:

Nymox Pharmaceutical Corporation is pleased to announce statistically significant clinical trial results showing that the Companys prostate enlargement (BPH) and prostate cancer drug Fexapotide Triflutate produced clinically important improvements in sexual function in first-line patients who received Fexapotide in the Companys U.S. long-term clinical trials.